{"brief_title": "Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder", "brief_summary": "Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D<sub>17</sub>] < 7) versus those subjects receiving placebo.", "condition": ["Major Depressive Disorder"], "intervention_type": ["Drug"], "intervention_name": ["DVS-233 SR"], "criteria": "Inclusion Criteria: - Subjects must have a primary diagnosis of major depressive disorder (MDD) - Depressive symptoms for at least 30 days prior to the screening visit - Minimum screening and study day -1 (baseline) scores of 20 on the Hamilton Psychiatric Rating Scale for Depression (HAM D<sub>17</sub>) Exclusion Criteria: - Treatment with DVS-233 SR at any time in the past - Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 - Known hypersensitivity to venlafaxine (IR or ER)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "keyword": "Depression, Involutional", "mesh_term": ["Disease", "Depressive Disorder", "Depression", "Depressive Disorder, Major"], "id": "NCT00063206"}